Publications by authors named "Jan Chandra Engel"
Article Synopsis
- This study investigates the impacts of skipping systematic biopsies during prostate cancer screening, utilizing data from the STHLM3-MRI trial with 7,609 men aged 50-74 at risk for prostate cancer.
- Results showed that omitting systematic biopsies decreased cancer detection rates, with a significant number of ISUP grade 1 cancers missed compared to the number of ISUP grade 2 and 3 cancers found.
- Ultimately, men undergoing targeted-only biopsies experienced fewer upgrades in cancer severity compared to those who had both targeted and systematic biopsies, suggesting that a selective biopsy approach might be more effective.
Background: Magnetic resonance imaging (MRI) followed by targeted biopsy (TBx) is utilized for prostate cancer (PCa) detection. However, the value of adding systematic biopsies (SBx) to targeted biopsy procedures (combined biopsy; CBx) in men with suspicious MRI findings has not been determined.
Methods: We analysed biopsy outcomes in 429 men with MRI lesions in the prospective multicenter STHLM3MRI pilot study, planned for prostate biopsy.
Article Synopsis
- * The study included men who died from prostate cancer in Stockholm County (2015-2019) and classified their PSA test history, revealing that 60% had no prior testing, 25% received delayed diagnoses, and only 15% were actively tested.
- * Results showed a concerning prevalence of high-risk (48%) and metastatic (27%) cancers, highlighting gaps in proactive PSA testing and the need for improved strategies for early detection and intervention.
Background: External validation of risk calculators (RCs) is necessary to determine their clinical applicability beyond the setting in which these were developed.
Objective: To assess the performance of the Rotterdam Prostate Cancer RC (RPCRC) and the Prostate Biopsy Collaborative Group RC (PBCG-RC).
Design Setting And Participants: We used data from the prospective, population-based STHLM3 screening study, performed in 2012-2015.
Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
Eur Urol Open Sci
February 2021
Article Synopsis
- In men over 50, lower urinary tract symptoms (LUTS) and prostate conditions like benign prostate hyperplasia and prostate cancer are prevalent, prompting guidelines for prostate-specific antigen (PSA) testing in those with LUTS for cancer detection.
- A study analyzed data from 4,588 men aged 50-69 with moderate LUTS and elevated PSA levels, comparing the effectiveness of PSA, PSA density, and the Stockholm3 blood test in identifying significant prostate cancer (sPCa).
- Results showed the Stockholm3 test was significantly better than PSA density and PSA at identifying sPCa, but limiting biopsies to men with higher PSA levels would miss a large percentage of detectable cancers, suggesting a careful balance in biopsy recommendations
There is conflicting evidence about the association between prostate cancer and Lower Urinary Tract Symptoms (LUTS). We aimed to describe the prevalence of LUTS and its association with prostate cancer risk. We studied the association between International Prostate Symptom Score (IPSS) and prostate cancer in a population-based sample of men ( = 45,595) aged 50-69 years from the Stockholm3 study.
View Article and Find Full Text PDF